Comparison of Serum Interleukin-10 (IL-10) Levels Between Normal Volunteers and Patients with Advanced Melanoma

REFERENCES

• Koh H. K. Cutaneous Melanoma. N. Engl. J. Med. 1991; 325: 171–182
   PubMed Web of Science ®Google Scholar
• Cutaneous Melanoma, C. M. Balch, A. N. Houghton, G. W. Milton, et al. 2nd Ed, J.B. Lippincott Co., Philadelphia 1992; 498–508
   Google Scholar
• Del Prete S. A., Maurer L. H., O’Donnell J., Forcier R. J., LeMarbre P. Combination Chemotherapy with Cisplatin, Carmustine, Decarbazine and Tamoxifen in Metastatic Melanoma. Cancer Treat. Rep. 1984; 68(11)1403–1405
   PubMedGoogle Scholar
• Sparano J. A., Dutcher J. P. Interleukin-2 for the Treatment of Advanced Melanoma. Melanoma 1993; 1(4)189–295
   Google Scholar
• Sosman J. A., Weiss G. R., Margolin K. A., Aronson F. R., Sznol M., Atkins M. B., O’Boyle K., Fisher R. I., Boldt D. H., Doroshow J. Phase IB Clinical Trial of Anti-CD3 Followed by High-Dose Bolus Interleukin-2 in Patients with Metastatic Melanoma and Advanced Renal Cell Carcinoma: Clinical and Immunologic Effects. J. Clin. Oncol. 1993; 11(8)1496–1505
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotzke M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. M., Lee R. E., Rubin J. T. A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone. N. Engl. J. Med. 1987; 316(15)889–897
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma: A Preliminary Report. N. Engl. J. Med. 1988; 316: 889–897
   Web of Science ®Google Scholar
• Nemunaitis J., Bohart C., Fong T., Meyer W., Edelman G., Paulson R. S., Orr D., Jain V., O’Brien J., Kuhn J., Kowal K. J., Burkeholder S., Bruce J., Ognoskie N., Wynne D., Martineau D., Ando D. Phase I Trial of Retroviral Vector-Mediated Gamma-Interferon (γ-IFN) Gene Transfer into Autologous Tumor Cells in Patients with Metastatic Melanoma. Cancer Gene Ther. 1998; 5(5)292–300
   PubMed Web of Science ®Google Scholar
• Sirott M. N., Bajorin D. R., Wong G. Y., Tao Y., Chapman P. B., Templeton M. A., Houghton A. N. Prognostic Factors in Patients with Metastatic Malignant Melanoma. A Multivariate Analysis. Cancer 1993; 72(10)3091–3198
   Google Scholar
• de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin-10 (IL-10) Inhibits Cytokine Synthesis by Human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes. J. Exp. Med. 1991; 174: 1209–1220
   PubMed Web of Science ®Google Scholar
• Tago K., Tosato G. IL-10 Inhibits T-Cell Proliferation and IL-2 Production. J. Immunol. 1992; 148: 1143–1148
   PubMed Web of Science ®Google Scholar
• Del Prete G., De Carli M., Almerigogna F., Giudizi M. G., Biagiotti R., Romagnani S. Human IL-10 Is Produced by Both Type 1 Helper (Th1) and Type 2 Helper (Th2) T-Cell Clones and Inhibits Their Antigen-Specific Proliferation and Cytokine Production. J. Immunol. 1993; 150: 353–360
   PubMed Web of Science ®Google Scholar
• de Waal Melefyt R., Haanen J., Spits H., Roncarolo M. G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J. E. Interleukin-10 (IL-10) and Viral IL-10 Strongly Reduce Antigen-Specific Human T-Cell Proliferation by Diminishing the Antigen-Presenting Capacity of Monocytes Via Downregulation of Class II Major Histocompatibility Complex Expression. J. Exp. Med. 1991; 174: 915–924
   PubMed Web of Science ®Google Scholar
• Ding L., Shevach E. M. IL-10 Inhibits Mitogen-Induced T-Cell Proliferation by Selectively Inhibiting Macrophage Colony-Stimulatory Function. J. Immunol. 1992; 148: 3133–3139
   PubMed Web of Science ®Google Scholar
• Enk A. H., Angeloni V. L., Udey M. C., Katz S. I. Inhibition of Langerhans Cell Antigen-Presenting Function by IL-10: A Role for IL-10 in Induction of Tolerance. J. Immunol. 1993; 151: 2390–2398
   PubMed Web of Science ®Google Scholar
• Cassatella M. A., Meda L., Bonora S., Ceska M., Constantin G. Interleukin-10 (IL-10) Inhibits the Release of Proinflammatory Cytokines from Human Polymorphonuclear Leukocytes. Evidence for an Autocrine Role of Tumor Necrosis Factor and IL-1-β in Mediating the Production of IL-8 Triggered by Lipopolysaccharide. J. Exp. Med. 1993; 178: 2207–2211
   PubMed Web of Science ®Google Scholar
• Ralph P., Nakoinz I., Sampson-Johannes A., Fong S., Lowe D., Min H. Y., Lin L. IL-10, T-lymphocyte Inhibitor of Human Blood Cell Production of IL-1 and Tumor Necrosis Factor. J. Immunol. 1992; 148: 808–814
   PubMed Web of Science ®Google Scholar
• Tripp C. S., Wolf S. F., Unanue E. R. Interleukin-12 and Tumor Necrosis Factor Alpha Are Costimulators of Interferon-Gamma Production by Natural Killer Cells in Severe Combined Immuno-Deficiency Mice with Listeriosis, and Interleukin-10 Is a Physiologic Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 3725–3729
   PubMed Web of Science ®Google Scholar
• Chernoff A. E., Granowitz E. V., Shapiro L., Vannier E., Lonnemann G., Angel J. B., Kennedy J. S., Rabson A. R., Wolff S. M., Dinarello C. A. A Randomized, Controlled Trial of IL-10 in Humans: Inhibition of Inflammatory Cytokine Production and Immune Response. J. Immunol. 1995; 154: 5492–5499
   PubMed Web of Science ®Google Scholar
• Qin L., Ding Y., Pahud D. R., Robson N. D., Shaked A., Bromberg J. S. Adenovirus-Mediated Gene Transfer of Viral IL-10 Inhibits the Immune Response to Both Alloantigen and Adenoviral Antigen. Human Gene Ther. 1997; 8: 1365–1374
   PubMed Web of Science ®Google Scholar
• Chaouat G., Tranchot J. Diallo, Volumenie J. L., Menu E., Gras G., Delage G., Mognetti B. Immune Suppression and Th1/Th2 Balance in Pregnancy Revisited: A (Very) Personal Tribute to Tom Wegmann. Am. J. Reprod. Immunol. 1997; 37(6)427–434
   PubMed Web of Science ®Google Scholar
• van Hogezand R. A., Verspaget H. W. New Therapies for Inflammatory Bowel Disease: An Update on Chimeric Anti-TNF Alpha Antibodies and IL-10 Therapy. Scand. J. Gastroenterol. 1997; 223(suppl)105–107
   Google Scholar
• Maini R. N., Elliott M., Brennan F. M., Williams R. O., Feldmann M. TNF Blockade in Rheumatoid Arthritis: Implications for Therapy and Pathogenesis. APMIS 1997; 105(4)257–263
   PubMed Web of Science ®Google Scholar
• Lattime E. C., Mastrangelo M. J., Berd D. Human Metastatic Melanoma Lesions and Cell Lines Express mRNA for IL-10. Proc. Am. Assoc. Cancer Res. 1994; 35: 489
   Google Scholar
• Chen O., Daniel V., Maher D. W., Hersey P. Production of IL-10 by Melanoma Cells: Examination of Its Role in Immunosuppression Mediated by Melanoma. Int. J. Cancer 1994; 56: 755
   PubMed Web of Science ®Google Scholar
• Gotlieb W. H., Abrams J. S., Watson T. J., Velu T. J., Berek J. S., Martinez-Mara O. Presence of Interleukin-10 (IL-10) in the Ascites of Patients with Ovarian and Other Intra-Abdominal Cancers. Cytokine 1992; 4: 385
   PubMed Web of Science ®Google Scholar
• Gastl G. A., Abrams J. S., Nanus D. M. Interleukin-10 Production by Human Carcinoma Cell Lines and Its Relationship to Interleukin-6 Expression. Int. J. Cancer 1992; 55: 96
   Web of Science ®Google Scholar
• Huang M. J., Wang P., Lee S., Sharma S., Mao J. T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S. M. Human Non-Small Cell Lung Cancer Cells Express a Type 2 Cytokine Pattern. Cancer Res. 1995; 55: 3847
   PubMed Web of Science ®Google Scholar
• Benjamin D., Knobloch T., Dayton M. Human B-cell Interleukin-10 B-Cell Lines Derived from Patients with Acquired Immunodeficiency Syndrome and Burkitt’s Lymphomas Constitutively Secrete Large Quantities of Interleukin-10. Blood 1992; 80: 1289
   PubMed Web of Science ®Google Scholar
• Nakagomi H., Dolcetti R., Bejarano M. T. The Epstein-Barr Virus Latent Membrane Protein-1 (LMP1) Induces Interleukin-10 in Burkitt Lymphoma Lines. Int. J. Cancer 1992; 57: 240
   Web of Science ®Google Scholar
• Avradopoulos K., Mehta S., Balckinton D., Wanebo H. J. Interleukin-10 as a Possible Mediator of Immunosuppressive Effect in Patients with Squamous Cell Carcinoma of the Head and Neck. Ann. Surg. Oncol. 1997; 4(2)184–190
   PubMed Web of Science ®Google Scholar
• Knoefel B., Nuske K., Steiner T., Junker K., Kosmehl H., Rebstock K., Reinhold D., Junker U. Renal Cell Carcinoma Produced IL-6, IL-10, IL-11, and TGF-beta 1 in Primary Cultures and Modulate T-Lymphocyte Blast Transformation. J. Interferon Cytokine Res. 1997; 17(2)95–102
   PubMed Web of Science ®Google Scholar
• Morisaki T., Katano M., Ikubo A., Anan K., Nakamura M., Nakamura K., Sato H., Tanaka M., Torisu M. Immunosuppressive Cytokines (IL-10, TGF-beta) Genes Expression in Human Gastric Carcinoma Tissues. J. Surg. Oncol. 1996; 63(4)234–239
   PubMed Web of Science ®Google Scholar
• Young M. R., Wright M. A., Lozano Y. Mechanisms of Immune Suppression in Patients with Head and Neck Cancer: Influence on the Immune Infiltrate of the Cancer. Int. J. Cancer 1996; 67(3)333–338
   PubMed Web of Science ®Google Scholar
• D’Odrazio T. J., Niederkorn J. Y. A Novel Role of TGF-β and IL-10 in the Induction of Immune Privilege. J. Immunol. 1998; 160: 2089–2098
   PubMed Web of Science ®Google Scholar
• Maeda H., Kuwahare H., Ichimura Y., Ohtsuki M., Kurakata S., Shiraishi A. TGF-Beta Enhances Macrophage Ability to Produce IL-10 in Normal and Tumor-Bearing Mice. J. Immunol. 1995; 155(10)4926–4932
   PubMed Web of Science ®Google Scholar
• Salazar-Onfray F., Charo J., Petersson M., Freland S., Noffz G., Qin Z., Blankenstein T., Ljunggren H. G., Kiessling R. Down-Regulation of the Expression and Function of the Transporter Associated with Antigen Processing in Murine Tumor Cell Lines Expressing IL-10. J. Immunol. 1997; 159(7)3195–3202
   PubMed Web of Science ®Google Scholar
• Richter G., Kruger-Krasagakes S., Hein G., Huls C., Schmitt E., Diamantstein T., Blankenstein T. IL-10 Transfected into Chinese Hamster Ovary Cells Prevents Tumor Growth and Macrophage Infiltration. Cancer Res. 1993; 53: 4134–4137
   PubMed Web of Science ®Google Scholar
• Rivoltini L., Joftus D. J., Squarcina P. Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Antitumor T-Cell Reactivity. Crit. Rev. Immunol. 1998; 18: 55–63
   PubMed Web of Science ®Google Scholar
• Leghass S. The Role of IFN-α in the Treatment of Metastatic Melanoma. Semin. Oncol. 1997; 24(suppl)24–31
   Google Scholar
• Sato T., McCue P., Masuoka K., Salwen S., Lattime E. C., Mastrangelo M. J., Berd D. Interleukin-10 Production by Human Melanoma. Clin. Cancer Res. 1996; 2: 1383–1390
   PubMed Web of Science ®Google Scholar
• Goldberg A. L., Rock K. L. Proteolysis, Proteasome and Antigen Presentation. Nature 1992; 357: 375
   PubMed Web of Science ®Google Scholar
• Ljunggren H. G., Paabo S. M., Cochet M., Kling G., Kourilsky P., Karre K. Molecular Analysis of H-2-Deficient Lymphoma Lines: Distinct Defects in Biosynthesis and Association of MHC Class I Heavy Chain and β2–Microglobulin Observed in Cells with Increased Sensitivity of NK Cell Lysis. J. Immunol. 1989; 142: 2911
   PubMed Web of Science ®Google Scholar
• Townsend A., Ohlen C., Bastin H., Ljunggren H. G., Foster L., Karre K. Association of Class I Major Histocompatibility Heavy and Light Chains Induced by Viral Peptides. Nature 1989; 340: 443
   PubMed Web of Science ®Google Scholar
• Fiorentino D. F., Zlotnic P., Viera T. IL-10 Acts on the Antigen-Presenting Cell to Inhibit Cytokine Production by TH-1 Cells. J. Immunol. 1991; 146: 3444
   PubMed Web of Science ®Google Scholar
• Taga K. G., Tosato G. IL-10 Inhibit T-Cell Proliferation and IL-2 Production. J. Immunol. 1992; 148: 1143
   PubMed Web of Science ®Google Scholar
• Groux H., Bigler M., de Vries J. E., Roncarolo M. G. IL-10 Induces a Long-Term Antigen-Specific Anergic State in Human CD4+ T-Cells. J. Exp. Med. 1996; 184: 19
   PubMed Web of Science ®Google Scholar
• Pisa P., Halapi E., Pisa E. K., Gerdin E., Hising C., Bucht A., Gerdin B., Kiessling R. Selective Expression of IL-10, IFN-γ and Granulocyte-Macrophage Colony-Stimulating Factor in Ovarian Cancer Biopsies. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 7708
   PubMed Web of Science ®Google Scholar
• Nakagomi H., Pisa P., Pisa E. K., Yamamoto Y., Halapi E., Backlin K., Juhlin C., Kiessling R. Lack of IL-2 Expression and Selective Expression of IL-10 mRNA in Human Renal Cell Carcinoma. Int. J. Cancer 1995; 63: 366
   PubMed Web of Science ®Google Scholar
• Kim J., Modlin R. L., Moy R. L., Dubinett S. M., McHugh T., Nickoloff B. J., Uyemura K. IL-10 Production in Cutaneous Basal and Squamous Cell Carcinomas: A Mechanism for Evading the Local T-cell Immune Response. J. Immunol. 1995; 155: 2240
   PubMed Web of Science ®Google Scholar
• Lattime E. C., Mastrangelo M. J., Bagasra O., Li W., Berd D. Expression of Cytokine mRNA in Human Melanoma Tissue. Cancer Immunol. Immunother. 1995; 41: 151
   PubMed Web of Science ®Google Scholar
• Kucharzik T., Lugering N., Winde G., Domschke W., Stoll R. Colon Carcinoma Cell Lines Stimulate Monocytes and Lamina Propria Mononuclear Cells to Produce IL-10. Clin. Exp. Immunol. 1997; 110: 296–302
   PubMed Web of Science ®Google Scholar
• Rook A. H., Kehrl J. H., Wakefield L. M., Robrts A. B., Sporn M. B., Burlington D. B., Lane H. C., Fauci A. S. Effects of Transforming Growth Factor β on the Functions of Natural Killer Cells: Depressed Cytolytic Activity and Blunting of Interferon Responsiveness. J. Immunol. 1986; 136(10)3916–3920
   PubMed Web of Science ®Google Scholar
• Kehrl J. H., Wakefield L. M., Roberts A. B., Jakowlew S., Alvarez-Mon M., Derynck R., Sporn M. B., Fauci A. S. Production of Transforming Growth Factor β by Human T-Lymphocytes and Its Potential Role in Regulation of T-Cell Growth. J. Exp. Med. 1986; 163: 1038–1049
   Google Scholar
• Ranges G. E., Figari I. S., Espevik T., Palladino M. A. Inhibition of Cytotoxic T-Cell Development by Transforming Growth Factor β and Reversal by Recombinant Tumor Necrosis Factor α. J. Exp. Med. 1987; 166: 991–998
   PubMed Web of Science ®Google Scholar
• Maeda H., Hiraishi A. TGF-beta Contributes to the Shift toward Th2-Type Responses Through Direct and IL-10-Mediated Pathways in Tumor-Bearing Mice. J. Immunol. 1996; 156(1)73–78
   PubMed Web of Science ®Google Scholar